• Explore /
  • Poster
  • / SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

Abstract Poster

Authors

null

Sacha Rothschild

University Hospital Basel, Basel, Switzerland

Sacha Rothschild , Alfred Zippelius , Spasenija Savic , Michel Gonzalez , Walter Weder , Alexandros Xyrafas , Corinne Rusterholz , Miklos Pless

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

SNCTP000001480

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS8573)

DOI

10.1200/JCO.2016.34.15_suppl.TPS8573

Abstract #

TPS8573

Poster Bd #

199b

Abstract Disclosures

Similar Posters

First Author: Sacha Rothschild

First Author: Sacha Rothschild

First Author: John M. Varlotto

First Author: Florian Guisier